110 related articles for article (PubMed ID: 27317516)
1. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions.
Nahmias Z; Nambudiri VE; Vleugels RA
J Am Acad Dermatol; 2016 Jul; 75(1):210-2. PubMed ID: 27317516
[No Abstract] [Full Text] [Related]
2. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
[No Abstract] [Full Text] [Related]
3. Use of lenalidomide in treating refractory prurigo nodularis.
Liu H; Gaspari AA; Schleichert R
J Drugs Dermatol; 2013 Mar; 12(3):360-1. PubMed ID: 23545923
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory prurigo nodularis with lenalidomide.
Kanavy H; Bahner J; Korman NJ
Arch Dermatol; 2012 Jul; 148(7):794-6. PubMed ID: 22801610
[No Abstract] [Full Text] [Related]
5. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
6. Treatment of prurigo nodularis with lenalidomide.
Ossorio-García L; Jiménez-Gallo D; Rodríguez-Mateos ME; Arjona-Aguilera C; Linares-Barrios M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27891738
[TBL] [Abstract][Full Text] [Related]
7. Necrobiotic xanthogranuloma treated with lenalidomide.
Mahendran P; Wee J; Chong H; Natkunarajah J
Clin Exp Dermatol; 2018 Apr; 43(3):345-347. PubMed ID: 29048134
[No Abstract] [Full Text] [Related]
8. Thalidomide and its dermatologic uses.
Paghdal KV; Schwartz R
Acta Dermatovenerol Croat; 2007; 15(1):39-44. PubMed ID: 17433179
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of lenalidomide in refractory lupus pernio.
Dalm VA; van Hagen PM
JAMA Dermatol; 2013 Apr; 149(4):493-4. PubMed ID: 23715134
[No Abstract] [Full Text] [Related]
10. Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
Caers J; Hafraoui K; Keutgens A; Caberg JH; Lambert F; Tassin F; Beguin Y
Eur J Haematol; 2014 Feb; 92(2):179-80. PubMed ID: 24299333
[No Abstract] [Full Text] [Related]
11. Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.
Portell C; Nand S
Blood; 2008 Apr; 111(8):4416-7. PubMed ID: 18398059
[No Abstract] [Full Text] [Related]
12. Response of cutaneous lesion of mantle cell lymphoma to lenalidomide.
Mishchenko E; Attias D; Tadmor T
Int J Hematol; 2014 Jul; 100(1):1-2. PubMed ID: 24838993
[No Abstract] [Full Text] [Related]
13. Successful treatment of Behçet's disease with lenalidomide.
Green J; Upjohn E; McCormack C; Zeldis J; Prince HM
Br J Dermatol; 2008 Jan; 158(1):197-8. PubMed ID: 17986298
[No Abstract] [Full Text] [Related]
14. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Anderson KC; Prince HM
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
[No Abstract] [Full Text] [Related]
15. Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report.
Rubinstein M; Assal A; Scherba M; Elman J; White R; Verma A; Strakhan M; Mohammadi F; Janakiram M
Am J Hematol; 2016 Feb; 91(2):E1. PubMed ID: 26502013
[No Abstract] [Full Text] [Related]
16. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
[No Abstract] [Full Text] [Related]
17. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
[No Abstract] [Full Text] [Related]
19. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
